gp130 cytokines, leukemia inhibitory factor and interleukin-6, induce neuropeptide expression in intact adult rat sensory neurons in vivo: time-course, specificity and comparison with sciatic nerve axotomy.
The gp130 cytokines leukemia inhibitory factor and interleukin-6 are neuroactive cytokines associated with peripheral nerve injury. Here we show that exogenous administration of these factors selectively regulates neuropeptide phenotype in intact sensory neurons in a manner consistent with their role as injury-induced factors. Intraneural injection of leukemia inhibitory factor into the intact sciatic nerve of adult rats induces a significant increase in the percentage of neuronal profiles immunoreactive for galanin in the L4 and L5 dorsal root ganglia without altering the percentage profiles immunoreactive for vasoactive intestinal polypeptide or neuropeptide Y. Galanin-immunoreactivity was predominantly confined to those neurons which retrogradely transported and accumulated leukemia inhibitory factor. The up-regulation of galanin-immunoreactivity observed in L4 and L5 dorsal root ganglia following unilateral axotomy of the sciatic nerve was significantly reduced following continuous treatment for two weeks with a monoclonal antibody against the gp130 receptor motif. Intraneural injection of interleukin-6 into the intact sciatic nerve also significantly increased the percentage of neuronal profiles which displayed galanin-immunoreactivity but not vasoactive intestinal polypeptide or neuropeptide Y-immunoreactivity. Our results indicate that cytokines which interact with the gp130 receptor at the site of peripheral nerve injury contribute to the cell body response to axotomy. Changes in the levels of such cytokines however are insufficient to account for the complete repertoire of neuropeptide phenotypic changes associated with peripheral nerve injury.
Thompson
S W
SW
Division of Physiology, UMDS. St Thomas's Hospital, London, UK.
Priestley
J V
JV
Southall
A
A
D000818:Animals; D019771:Axotomy; D058966:Contactins; D016207:Cytokines / Q000008:administration & dosage / Q000494:pharmacology*; D019085:Fluorescent Antibody Technique, Direct; D019004:Galanin / Q000096:biosynthesis; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D007150:Immunohistochemistry; D015850:Interleukin-6 / Q000008:administration & dosage / Q000494:pharmacology*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D019006:Neural Cell Adhesion Molecules / Q000378:metabolism*; D009475:Neurons, Afferent / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D009478:Neuropeptide Y / Q000096:biosynthesis; D009479:Neuropeptides / Q000096:biosynthesis*; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000502:physiology*; D013997:Time Factors
D058966:Contactins; D016207:Cytokines; D006131:Growth Inhibitors; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D019006:Neural Cell Adhesion Molecules; D009478:Neuropeptide Y; D009479:Neuropeptides; D019004:Galanin